Home Featured Page 122

Featured

Latest

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine...

Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT...

Psychedelics Weekly – Field Trip Health Closes Five Clinics, Legalization Bills...

PT399 – Vital Psychedelic Conversations

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100...

MYDECINE INNOVATIONS GROUP ANNOUNCES COMMON SHARE SUBSCRIPTION AGREEMENT

Reunion Sues Mindset, Claims it Copied RE104

Field Trip Health & Wellness to Close Clinics in 5 Locations

Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for...

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine...

Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT...

Psychedelics Weekly – Field Trip Health Closes Five Clinics, Legalization Bills...

PT399 – Vital Psychedelic Conversations

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100...

MYDECINE INNOVATIONS GROUP ANNOUNCES COMMON SHARE SUBSCRIPTION AGREEMENT

Reunion Sues Mindset, Claims it Copied RE104

Field Trip Health & Wellness to Close Clinics in 5 Locations

Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for...

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY